Physician profile
Felipe Lugo
NPI 1942658174
$1,006.15
in general payments reported to CMS, 2019-2025
16 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.87 · 2020: $229 · 2021: $201 · 2022: $169 · 2023: $163 · 2024: $16.86 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $306.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $160.58 | 2019-2021 | |
| Lilly USA, LLC | $146.43 | 2019-2023 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $141.14 | 2022-2023 | |
| Pfizer INC. | $94.25 | 2021-2023 | |
| Novo Nordisk INC | $86.96 | 2020-2025 | Wegovy |
| Glaxosmithkline, LLC. | $56.14 | 2020-2021 | |
| Amgen INC. | $46.21 | 2025 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $46.00 | 2019-2020 | |
| Esperion Therapeutics, INC. | $41.61 | 2022-2023 | Nexletol |
| Avanir Pharmaceuticals, INC. | $35.86 | 2019-2021 | |
| Corcept Therapeutics | $35.76 | 2024-2025 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $32.01 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $29.40 | 2021-2022 | |
| Abbott Laboratories | $23.95 | 2025 | Freestyle Libre |
| Sanofi Pasteur INC. | $15.12 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $14.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felipe Lugo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.